LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

MAP Group joins EuropaBio: supporting patient access in Europe

11/12/2024

PRESS RELEASE

Brussels, 11 December 2024 - EuropaBio is pleased to announce that the MAP Group, a growing pan-European consultancy partnering with health technology developers to achieve successful patient access across Europe, has joined as a member.

The MAP Group offers integrated consultancy services across Market Access and HEOR, Regulatory Strategy and Compliance and Medical and Scientific Affairs. Through its expertise and activities, it helps biopharma companies reach the European market and, ultimately, bring innovative therapies to patients. With local expertise and a global perspective, the team expertly navigate complex market dynamics, providing tailored, intelligent solutions that navigate the complexities of regulatory pathways and optimise market entry. Their online membership platform provides uninterrupted access to experts as well as an extensive and unique database, set of tools and invaluable content, to a wide range of pharmaceutical and biotech companies across Europe.

As the group expands its expertise across Europe, it addresses the needs of both large and small innovators by contributing unique perspectives and expertise from its teams across the UK, Ireland, Benelux, and Germany.  

Dr. Claire Skentelbery, Director General of EuropaBio had this to say, “MAP becoming part of EuropaBio strengthens the expertise and knowledge required to build a thriving and sustainable healthcare system in Europe, from which patients are the beneficiaries and Europe’s innovative industries can anchor and grow.”

Steve Glass, Group CEO said, “It is a pleasure to join EuropaBio. We are keen to foster collaboration and engage in meaningful dialogue with fellow members and other European stakeholders, by representing the unique views of our diverse client base. As our footprint across geographies increases, we are looking forward to working closely with EuropaBio in our shared drive to champion a healthy Biotech sector and access for patients in Europe.”

For more information about the MAP Group visit www.mappatientaccess.com

MAP Group joins EuropaBio: supporting patient access in Europe


Download
Share
Francesca Degli Agostini
Francesca Degli Agostini

Related posts

22/05/2025

Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World


Read more
21/05/2025

Ensuring Biotech Integration in the Single Market


Read more
16/04/2025

EuropaBio position on the EU Life Sciences Strategy


Read more

Important links

  • Adisseo joins EuropaBio: Feeding Animals Sustainably Around the World
  • Ensuring Biotech Integration in the Single Market

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.